CLRB - Cellectar Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0200
+0.0300 (+1.51%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.9900
Open2.1600
Bid1.95 x 800
Ask1.98 x 800
Day's Range1.7186 - 2.3900
52 Week Range1.2200 - 14.0000
Volume273,069
Avg. Volume61,754
Market Cap9.611M
Beta (3Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-8.25
Earnings DateMar 19, 2019 - Mar 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.20
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

    FLORHAM PARK, N.J., Jan. 07, 2019 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire18 days ago

    Cellectar Biosciences to Present at the Biotech Showcase

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview at the Biotech Showcase on Monday, January 7, 2019 at 10:00am Pacific Time.  The conference will be held at the Hilton San Francisco Union Square January 7-9, 2019. Cellectar's product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs™) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors.

  • GlobeNewswirelast month

    Cellectar Granted Japanese Patent for CLR 131

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the Japan Patent Office has granted the patent titled “Phospholipid Analogs as Diapeutic Agents and Methods of Use Thereof” with application number 2016135920.  The patent provides composition of matter and use protection for the company’s proprietary phospholipid ether (PLE) analogs and specifically CLR 131 in breast, brain, leukemias and a variety of other cancers.

  • GlobeNewswire2 months ago

    Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

    FLORHAM PARK, N.J., Dec. 04, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • Analysts Take Action on Health Care Stocks
    GuruFocus.com2 months ago

    Analysts Take Action on Health Care Stocks

    The analyst established a price target of $174 per share, which represents 38.3% upside from the share price of $125.8 at market close on Tuesday. The share price has increased 46% over the 52 weeks of trading through Nov. 20. Warning! GuruFocus has detected 6 Warning Signs with BGNE.

  • GlobeNewswire2 months ago

    Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

    Cellectar Biosciences, Inc. (CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported financial results for the three and nine months ended September 30, 2018 and provided a business update. Announced that the U.S. Food and Drug Administration has granted an exemption to the Import Alert for CLR 131 in all hematology indications, effective immediately.  The company continues to work with the appropriate division of the FDA to obtain an exemption for its pediatric program, evaluating CLR 131 in multiple childhood cancers with significant unmet medical need.

  • GlobeNewswire2 months ago

    Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC), the sole supplier of the CLR 131. The exemption for CLR 131 is effective immediately for all hematology studies and, in response, Cellectar is preparing to dose patients in the second fractionated dose cohort of the Phase 1 relapsed refractory (R/R) multiple myeloma study and the Phase 2 study for R/R hematologic malignancies.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences

    NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Dow ...

  • GlobeNewswire4 months ago

    Cellectar Biosciences Provides an Update on the FDA Import Alert

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has initiated direct talks with the company concerning a possible exemption for CLR 131 from the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC), the sole supplier of Cellectar’s drug CLR 131.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! TAL Education Group (ADR) (NYSE: TAL ) stock was trading ...

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Cara Therapeutics and Cellectar Biosciences

    NEW YORK, NY / ACCESSWIRE / July 18, 2018 / U.S. stocks closed up on Tuesday, as the Federal Reserve announced that it would be flexible in the face of changing conditions and will not move too quickly ...